Quantum Biopharma (QNTM) EBIT (2019 - 2026)

Quantum Biopharma has disclosed EBIT across 8 years of filings, most recently posting -$3.0 million for Q1 2026.

• EBIT for Q1 2026 came in at -$3.0 million, up 12.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.9 million (down 13.29% YoY), and the FY2025 annual result was -$15.3 million, up 5.17% from the prior year.
• EBIT came in at -$3.0 million for Q1 2026 at Quantum Biopharma, down from -$2.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $25.3 million in Q2 2023 to a low of -$9.8 million in Q1 2023.
• The 5-year median for EBIT is -$3.4 million (2023), against an average of -$1.4 million.
• Across the five-year window, EBIT tumbled 274.26% in 2023 and soared 77.07% in 2024, its largest moves.
• Quantum Biopharma's EBIT stood at $5.6 million in 2022, then sank by 227.63% to -$7.2 million in 2023, then soared by 70.99% to -$2.1 million in 2024, then declined by 13.48% to -$2.4 million in 2025, then fell by 24.98% to -$3.0 million in 2026.
• The last three EBIT figures came in at -$3.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.